The number of genes a cell uses to make RNA is a reliable indicator of how developed the cell is, research finds.
The finding could make it easier to target cancer-causing genes, researchers report.
Cells that initiate cancer are thought to be stem cells, hard-to-find cells that can reproduce themselves and develop, or differentiate, into more specialized tissue, such as skin or muscle—or, when they go bad, into cancer.
“Right now, targeted therapies are focused on specific genes or molecules, the vast majority of which may not be specific to cancer stem cells,” says senior author Aaron Newman, assistant professor of biomedical data science and a member of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University.
“Usually these therapies don’t work for very long. But if you can identify the least-differentiated cells and then look for markers specific to them, it’s no longer a guessing game to find the genes to target.”
The study’s finding is also significant because identifying stem cells of various tissue types is an important step toward regenerating damaged or malfunctioning tissues.
Tracking down cancer cells
As stem cells become more differentiated and more like adult cells, they express fewer and fewer genes, the researchers find. Previously, other researchers had noticed this correlation and thought it might be an interesting coincidence. But Newman and his colleagues were the first to sort through thousands of single-cell genetic tests in public databases and prove this pattern was consistent and reliable.
Newman and co-lead author Gunsagar Gulati, an MD-PhD student, combined the measurement of the number of genes expressed in a cell with the measurement of the number of RNA copies created per gene as the basis for a computer algorithm, CytoTRACE, designed to determine how developmentally advanced cells are.
Cancerous tumors can contain many millions of cells, each of which may have thousands of gene mutations. The cells in a tumor are diverse. Most will be differentiated cells that die out naturally on their own, while relatively few are the more dangerous cancer stem cells, or tumor-initiating cells. These cells are hard to find and therefore hard to characterize using current methods, but far easier to find with CytoTRACE.
“As a cancer researcher, what I find most exciting is that this tool helps us find the tumor-initiating cells that have long been known to be responsible for resistance to treatment, metastasis, and relapse after treatment,” says co-lead author Shaheen Sikandar, an instructor at the Institute for Stem Cell Biology and Regenerative Medicine.
Better than ‘educated guessing’
Coauthor Michael Clarke, a professor of medicine, was the first researcher to identify cancer stem cells in a solid tumor. Clarke says that CytoTRACE, which analyzes data on all the RNA created in a single cell, can quickly recapitulate research that takes years using traditional methods.
“The way that we currently find cell markers for cancer stem cells is to make educated guesses about which markers will likely be important, then sort those cells and look for stem cell activity,” says Clarke, also professor in cancer biology and associate director of the Institute for Stem Cell Biology and Regenerative Medicine.
Researchers can look at relatively few markers at a time, so it takes a lot of sorting and analysis, and in the end, they will likely be only partially successful in finding good markers of the stem cells they are looking for, he says. “What CytoTRACE allows us to do is first find the stem or progenitor cells, then look at what unique markers they have on them.”
In the paper, the researchers describe using CytoTRACE to query single-cell RNA data for triple-negative breast cancer, a type of tumor that is rarer but more dangerous because tumor growth doesn’t rely on the biochemical pathways that physicians usually target to treat breast cancer. Not only did CytoTRACE identify known markers of cancer stem cells, it also spotted a marker that had not been previously been thought to be important.
“This one gene looks like it has amazing potential as a therapeutic,” Clarke says.
‘The inner workings of cell change’
CytoTRACE also has the potential to transform how researchers hunt for stem cells associated with other diseases, Newman says. “This tool could also be useful in finding treatments for disorders such as Alzheimer’s or other degenerative diseases where loss of stem cell function might be part of the disease process,” he says.
Regenerative medicine, in which diseased or damaged tissue is repaired through the activity of stem cells, requires the ability to isolate purified populations of stem cells specific to a given tissue. To regrow bone, the heart or the eyes, for example, researchers must first find the stem cells responsible for regrowing those organs. Finding the markers that are specific to these normal stem cells has been much like the process for finding cancer stem cell markers, the researchers say—that is, the product of educated guesses, luck and a lot of work in the lab. CytoTRACE could significantly shorten that process.
“One of the main motivations behind developing CytoTRACE was to create a tool for rapid and accurate identification of stem cells in humans,” Gulati says. “But another important question we hope to answer is how the inner workings of a cell change as the cell transforms from one state to another. This research opens up a whole new avenue of research to study how global changes in gene expression and DNA structure influence a cell’s state.”
Overall, Newman says, the study shows the power and promise of using big data to advance biology and medicine through computer research that complements discoveries made in the lab.
“It wouldn’t have been possible to gather all this data in our lab, but by using public databases and asking the right questions, it’s more and more possible to make fundamental discoveries in biology and medicine,” he says.
The research appears in Science.
Support for the research came from the National Institutes of Health, the Stinehart-Reed Foundation, Stanford Bio-X, the Virginia and DK Ludwig Fund for Cancer Research, the US Department of Defense, the National Science Foundation, and the Stanford Medical Science Training Program.
Source: Christopher Vaughn for Stanford University
